The compound is currently being evaluated for Trk brain imaging and tumor imaging in TrkA-TPM3 (IC50 = 162 nM) overexpressing colon carcinoma KM12 mice tumor xenografts and other neoplasms bearing diverse NTKR fusions. Here, TPM3 is linked to neoplasm.